ChiCTR1900025588 版本V1.1 版本创建时间2019/09/02 06:26:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900025588 

最近更新日期:

Date of Last Refreshed on:

2019-09-02 06:26:06 

注册时间:

Date of Registration:

2019-09-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

该研究尚未获得伦理委员会批准。请于批准后才开始纳入参试者,并与我们联系上传批件。 髓内钉联合外侧壁钢板治疗全粗隆间骨折的随机对照研究

Public title:

A randomized control trial for combined proximal femur intramedullary nail and lateral wall plate for the treatment of pantrochanteric fracture

注册题目简写:

English Acronym:

研究课题的正式科学名称:

髓内钉联合外侧壁钢板治疗全粗隆间骨折的随机对照研究

Scientific title:

A randomized control trial for combined proximal femur intramedullary nail and lateral wall plate for the treatment of pantrochanteric fracture

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龙安华 

研究负责人:

龙安华 

Applicant:

Long Anhua 

Study leader:

Long Anhua 

申请注册联系人电话:

Applicant telephone:

+86 18911123487

研究负责人电话:

Study leader's telephone:

+86 18911123487

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nankaims@163.com

研究负责人电子邮件:

Study leader's E-mail:

nankaims@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京通州新华南路82号

研究负责人通讯地址:

北京通州新华南路82号

Applicant address:

82 South Xinhua Road, Tongzhou District, Beijing, China

Study leader's address:

82 South Xinhua Road, Tongzhou District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

101100

研究负责人邮政编码:

Study leader's postcode:

101100

申请人所在单位:

北京潞河医院

Applicant's institution:

Beijing Luhe hospital, Capital Medical University

研究负责人所在单位:

北京潞河医院

Affiliation of the Leader:

Beijing Luhe hospital, Capital Medical University

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京潞河医院

Primary sponsor:

Beijing Luhe Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京通州新华南路82号

Primary sponsor's address:

82 South Xinhua Road, Tongzhou District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

北京市科委

Source(s) of funding:

Science and Technology Commission of Beijing

Target disease:

pantrochanteric fracture

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对比髓内钉联合外侧壁钢板和单纯髓内钉治疗全粗隆间骨折的优缺点,验证髓内、外联合固定的理念,明确联合固定在降低失败率及并发症发生率的优势。  

Objectives of Study:

To compare the advantages and disadvantages of intramedullary nail combined with external wall plate and simple intramedullary nail in the treatment of total intertrochanteric fractures. To validate the concept of intramedullary and plate fixation, and to identify the advantages of combined fixation in reducing failure rate and complication rate.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 年龄大于60岁,性别不限;
(2) 诊断为内外侧不稳定型股骨全粗隆间骨折(Babhulkar改良分型B 型和 C 型骨折);
(3) 患者于我院接受手术治疗;
(4) 签署本研究知情同意书。

Inclusion criteria

(1) Aged >=60 years old male and female;
(2) Diagnosis of internal and external unstable femoral intertrochanteric fractures (Babhulkar modified type B and C fractures);
(3) The patient is undergoing surgery in our hospital;
(4) Sign the informed consent form for this study.

排除标准:

(1) 严重的骨性关节炎、风湿或类风湿关节炎或病理性骨折;
(2) 合并下肢的严重损伤(如合并同侧或对侧的足、踝胫腓骨、膝关节或股骨折;合并下肢的踝、膝、髋关节脱位;合并股骨头骨折);
(3) 合并髋周软组织或骨感染;
(4) 合并有骨质疏松以外的代谢性骨病(如Paget 骨病,肾性骨萎缩、骨软化症;
(5) 合并中重度认知功能损害;
(6) 严重的老年痴呆与帕金森病等明显影响行走能力,不利于术后康复;
(7) 患者或其家属不同意参加本研究者。

Exclusion criteria:

(1) severe osteoarthritis, rheumatism or rheumatoid arthritis or pathological fractures;
(2) combined with severe injury to the lower extremities (such as the ipsilateral or contralateral foot, tibia, knee or femoral fracture; combined with the lower extremity of the ankle, knee, hip dislocation; combined with femoral head fracture);
(3) combined with soft tissue or bone infection of the hip;
(4) Combined with metabolic bone diseases other than osteoporosis (such as Paget bone disease, renal bone atrophy, osteomalacia;
(5) merging moderate to severe cognitive impairment;
(6) Severe Alzheimer's disease and Parkinson's disease can significantly affect walking ability, which is not conducive to postoperative rehabilitation;
(7) The patient or his or her family does not agree to participate in the study.

研究实施时间:

Study execute time:

From 2019-10-01 00:00:00 To 2021-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-10-01 00:00:00 To 2020-10-31 00:00:00  

干预措施:

Interventions:

组别:

实验组

样本量:

38

Group:

Experimental group

Sample size:

干预措施:

髓内钉+外侧壁板

干预措施代码:

Intervention:

Nail + lateral plate

Intervention code:

组别:

对照组

样本量:

38

Group:

Control Group

Sample size:

干预措施:

髓内钉

干预措施代码:

Intervention:

Nail

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

北京市 

Country:

China 

Province:

Beijing 

City:

Beijing 

单位(医院):

首都医科大学附属北京潞河医院 

单位级别:

三级医院 

Institution
hospital:

Beijing Luhe hospital, Capital Medical University

Level of the institution:

Tertiary Hospital

测量指标:

Outcomes:

指标中文名:

内固定失效率

指标类型:

主要指标

Outcome:

Failure rate of implants

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨折相关并发症

指标类型:

主要指标

Outcome:

Fracture associated complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

Operative time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术出血量

指标类型:

次要指标

Outcome:

Blood loss during surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内科并发症

指标类型:

次要指标

Outcome:

Medical complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS 评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Harris 评分

指标类型:

次要指标

Outcome:

Harris score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NONE

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过随机数表法产生随机数,分配给每一例入组患者。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random numbers were generated by random number table method and assigned to each patient enrolled.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://wwww.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子版CRF及EDC系统采集管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use electronic CRF and EDC system to collection and management data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-09-02 06:09:25